A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 days after vaccination were infections and infestations, occurring in 10·0–20·5% of participants.
The Lancet Infectious Diseases published a clinical update in Infectious Disease on 01 Apr 2026.
The item focuses on Research in brief.
Review the original article for the full source wording and details.